Jeffrey H. Chen

Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor

Matthew R. Janes, Jingchuan Zhang, Lian‐Sheng Li et al. · Cell · 2018 · 1.2K citations · Full text

Pharmacy, Medicinal Chemistry, Oncology +12

Selective Inhibition of Oncogenic KRAS Output with Small Molecules Targeting the Inactive State

Matthew P. Patricelli, Matthew R. Janes, Lian‐Sheng Li et al. · Cancer Discovery · 2016 · 754 citations · Full text

Medicine, Medicinal Chemistry, Oncology +17

Nonclinical Antiangiogenesis and Antitumor Activities of Axitinib (AG-013736), an Oral, Potent, and Selective Inhibitor of Vascular Endothelial Growth Factor Receptor Tyrosine Kinases 1, 2, 3

Dana D. Hu‐Lowe, Helen Y. Zou, Maren L. Grazzini et al. · Clinical Cancer Research · 2008 · 628 citations

Medicine, Oncology, Pharmacology +17

Molecular conformations, interactions, and properties associated with drug efficiency and clinical performance among VEGFR TK inhibitors

Michele McTigue, Brion W. Murray, Jeffrey H. Chen et al. · Proceedings of the National Academy of Sciences · 2012 · 571 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +14

Targeting Activin Receptor-Like Kinase 1 Inhibits Angiogenesis and Tumorigenesis through a Mechanism of Action Complementary to Anti-VEGF Therapies

Dana D. Hu‐Lowe, Enhong Chen, Lianglin Zhang et al. · Cancer Research · 2011 · 133 citations · Full text

Medicine, Oncology, Pharmacology +17